Latest Articles

Publication Date
Scientists discover high-risk form of endometrial cancer—and how to test for it—using AI - Medical Xpress

Scientists discover high-risk form of endometrial cancer—and how to test for it—using AI Medical Xpress

Published: June 26, 2024, 7 a.m.
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients - BioPharm International

AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients BioPharm International

Published: June 20, 2024, 7 a.m.
FDA approves MSD’s KEYTRUDA for endometrial carcinoma - Pharmaceutical Technology

FDA approves MSD’s KEYTRUDA for endometrial carcinoma Pharmaceutical Technology

Published: June 18, 2024, 7 a.m.
Novel immunotherapy combination approved for endometrial cancer - European Pharmaceutical Review

Novel immunotherapy combination approved for endometrial cancer European Pharmaceutical Review

Published: June 18, 2024, 7 a.m.
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval - FiercePharma

Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval FiercePharma

Published: June 18, 2024, 7 a.m.
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? - FiercePharma

AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? FiercePharma

Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval - Pharmaceutical Technology

AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval Pharmaceutical Technology

Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive

FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive

Published: June 17, 2024, 7 a.m.
Interleukin-1β induces and accelerates human endometrial stromal cell senescence and impairs decidualization via the c-Jun N-terminal kinase pathway | Cell Death Discovery - Nature.com

Interleukin-1β induces and accelerates human endometrial stromal cell senescence and impairs decidualization via the c-Jun N-terminal kinase pathway | Cell Death Discovery Nature.com

Published: June 15, 2024, 7 a.m.
Women’s Health and Wellbeing Summit to 'normalise conversations' about women's health - Women's Agenda

Women’s Health and Wellbeing Summit to 'normalise conversations' about women's health Women's Agenda

Published: June 12, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!